QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-42

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $4...

 alzamend-neuro-q1-eps-128-misses-069-estimate

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0....

 ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-45

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $18...

 alzamend-neuro-alzn-stock-surges-on-al001-phase-ii-trial-milestone

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims fo...

 alzamend-neuro-enrolls-first-patient-of-first-phase-ii-clinical-study-of-al001-in-healthy-human-subjects-topline-data-expected-by-year-end

Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted fo...

 alzamend-neuro-announces-phase-ii-trial-of-al001-for-alzheimers-in-q4-2025-in-partnership-with-massachusetts-general-hospital

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel...

 alzamend-neuro-plans-initiation-date-of-phase-ii-clinical-trial-of-al001-for-major-depressive-disorder

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood an...

 ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-20

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $32...

 alzamend-neuro-to-present-non-clinical-data-update-on-pharmacokinetics-of-al001-a-lithium-salicylatel-proline-co-crystal-as-a-potentially-beneficial-lithium-sparing-treatment-for-bipolar-disorder-type-1-alzheimers-disease-major-depressive-disorder-and-post-traumatic-stress-disorder-at-the-society-of-toxicology-2025-annual-meeting-and-toxexpo

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lit...

 ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-32

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $35...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION